Signifor LAR FDA Approval History
FDA Approved: Yes (First approved December 15, 2014)
Brand name: Signifor LAR
Generic name: pasireotide
Dosage form: for Injectable Suspension
Company: Novartis Pharmaceuticals Corporation
Treatment for: Acromegaly
Signifor LAR (pasireotide) is a long acting a somatostatin analog formulation for the treatment of patients with acromegaly.
Development timeline for Signifor LAR
| Date | Article |
|---|---|
| Dec 16, 2014 | Approval Novartis Gains FDA Approval for Signifor LAR to Treat Patients with Acromegaly |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
